Trial Profile

Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entecavir (Primary)
Indications Hepatic fibrosis; Hepatitis B
Focus Therapeutic Use
Acronyms INFIRE; INFIRE-001

Most Recent Events

22 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
11 Aug 2012 Actual initiation date 17 Dec 2010 added as reported by EudraCT.
27 Apr 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com